Extensions — US Patent 10980926

Term, Adjustments, and Related Applications for US 10,980,926

Based on a thorough review of the United States Patent and Trademark Office (USPTO) records for US Patent 10,980,926, the following details regarding its term, related applications, and expiration have been compiled.

Patent Term Adjustments and Extensions

Patent Term Adjustment (PTA): A review of the prosecution history for US Patent 10,980,926 indicates that there has been no Patent Term Adjustment granted. The patent's term is therefore the standard 20 years from its earliest effective filing date.
Patent Term Extension (PTE): There is no indication of any filed or granted Patent Term Extension under 35 U.S.C. § 156. Such extensions are typically sought for delays caused by regulatory review (e.g., by the Food and Drug Administration) and are not applicable in this case.

Continuation and Divisional Applications

US Patent 10,980,926 is a continuation of a prior application.

Parent Application: This patent is a continuation of U.S. Application No. 15/608,183, which was filed on May 30, 2017. This parent application has since issued as US Patent 10,758,652.

Patent Family

This patent is part of a larger family of related applications that claim priority to the original 2017 filing. This indicates a strategy by Haemonetics Corp. to build a portfolio of patents around this technology. Notable US family members include:

US 10,758,652: The parent patent from which this patent is a continuation.
US 11,738,124: A continuation of this patent's parent application.
US 12,171,916: A continuation of US 10,980,926.
US 12,324,873: A continuation of US 11,738,124.
US 2025/0269097 A1: A pending application that is a continuation of US 12,171,916.

This extensive family of continuing applications demonstrates an ongoing effort to protect various aspects and improvements of the core invention.

Projected Expiration Date

The term of a US patent is 20 years from the filing date of the earliest U.S. or international (PCT) application to which priority is claimed.

Priority Date: May 30, 2017 (from application 15/608,183)
Standard Term: 20 years from the priority date.
Projected Expiration: May 30, 2037

This projected expiration date does not account for any potential disclaimers or a failure to pay required maintenance fees, which are due at 3.5, 7.5, and 11.5 years from the issue date of April 20, 2021. The current status of the patent is active, indicating that all fees have been paid to date.